grant
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection
Organization LSU HEALTH SCIENCES CENTERLocation NEW ORLEANS, UNITED STATESPosted 16 Sept 2024Deadline 30 Jun 2029
NIHUS FederalResearch GrantFY20253-D3-Dimensional3DAIDS VirusAIDS preventionAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAdherens JunctionAdhering JunctionAdhesive JunctionAdverse effectsAnchoring JunctionAntiproteasesArchitectureBiopsyBody TissuesBuccal MucosaCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCell BodyCell LineCellLineCellsClinicalClinical ManagementClinical ResearchClinical StudyDataDesmosomesDiseaseDisorderDropsEndopeptidase InhibitorsEngineering / ArchitectureEpitheliumExhibitsExposure toGeneral PopulationGeneral PublicGeneralized GrowthGingivaGingivalGroups at riskGrowthHIVHIV InfectionsHIV PreventionHIV SeronegativitiesHIV SeronegativityHIV negativeHIV therapyHIV/AIDS preventionHNSCCHPVHPV 16HPV associated HNSCCHPV driven HNSCCHPV driven head and neck cancerHPV infectionHPV preventionHPV screeningHPV testingHPV(+) HNSCCHPV(+) head and neck squamous cell carcinomaHPV+ HNSCCHPV+ head and neck cancersHPV-16HPV-associated head and neck cancerHPV-associated head and neck squamous cell carcinomaHPV-positive HNSCCHPV-positive head and neck cancersHPV-related HNSCCHPV-related head and neck squamous cell carcinomaHPV16HTLV-III InfectionsHTLV-III SeronegativitiesHTLV-III SeronegativityHTLV-III-LAV InfectionsHead and Neck CancerHead and Neck CarcinomaHead and Neck Squamous Cell CarcinomaHealthHistopathologyHuman Immunodeficiency VirusesHuman Papilloma VirusHuman Papilloma Virus screeningHuman PapillomavirusHuman T-Lymphotropic Virus Type III InfectionsHuman papilloma virus infectionHuman papilloma virus type 16Human papillomavirus 16Human papillomavirus driven HNSCCHuman papillomavirus driven head and neck cancerHuman papillomavirus infectionHuman papillomavirus preventionHuman papillomavirus type 16ImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImpairmentIn VitroIncidenceIndividualInfectionInfectious Human Wart VirusIntervention StrategiesInvestigatorsLAV-HTLV-IIILesionLymphadenopathy-Associated VirusLymphocyte CountLymphocyte NumberMacula AdherensMaintenanceMalignant Head and Neck NeoplasmMediatingModelingMouth DiseasesMouth MucosaMucosaMucosal TissueMucous MembraneNode of BizzozeroOccluding JunctionsOncogenicOralOral Cavity DiseaseOral Cavity DisorderOral DiseaseOral DisorderOral MucosaOral PathologyOral mucous membrane structurePathologyPatient riskPatientsPeople at riskPeptidase InhibitorsPeptide Hydrolase InhibitorsPeptide Peptidohydrolase InhibitorsPermeabilityPersonsPersons at riskPopulationPopulations at RiskPrEPPredispositionPrevalenceProtease AntagonistsProtease InhibitorProteinase InhibitorsRegimenReportingResearch PersonnelResearchersResidualResidual stateRiskRisk FactorsRoleSCCHNSamplingSpot DesmosomeStrains Cell LinesStratified EpitheliumStratified Squamous EpitheliumSusceptibilityT4 CellsT4 LymphocytesTestingTight JunctionsTimeTissue GrowthTissue ModelTissuesTotal Lymphocyte CountToxic effectToxicitiesViral BurdenViral DiseasesViral LoadViral Load resultVirusVirus DiseasesVirus-HIVZonula Occludensantiretroviral therapyantiretroviral treatmentcultured cell linehead and neck squamous carcinomahead and neck squamous cell cancerhead/neck cancerhigh risk grouphigh risk individualhigh risk peoplehigh risk populationhuman papilloma virus 16human papilloma virus+ head and neck squamous cell carcinomahuman papillomavirus associated head and neck cancerhuman papillomavirus associated head and neck squamous cell carcinomahuman papillomavirus based testinghuman papillomavirus driven head and neck squamous cell carcinomahuman papillomavirus induced head and neck squamous cell carcinomahuman papillomavirus positive HNSCChuman papillomavirus positive head and neck cancershuman papillomavirus positive head and neck squamous cell carcinomahuman papillomavirus related head and neck squamous cell carcinomahuman papillomavirus testingin vivoinfection riskmalignant head and neck tumormouth disorderontogenyoral HPVoral HPV infectionoral HPV-positive HNSCCoral HPV-positive head and neck cancersoral human papilloma virus infectionoral human papillomavirusoral human papillomavirus infectionoral human papillomavirus positive head and neck cancersoral human papillomavirus positive head and neck squamous cell carcinomaoral mucosaeoral mucosaloral papillomavirus infectionoral tissuepatient centeredpatient orientedpatient populationpre-exposure prophylaxispreventprevent HPVprevent human papillomaviruspreventingprospectiveprotein expressionrepairrepairedscreeningscreeningssocial rolesuccessthree dimensionaltype 16 Human papilloma virustype 16 Human papillomavirusviral infectionvirus infectionvirus-induced diseasevolunteerwart virus
Description preview
ABSTRACT
People living with human immunodeficiency virus (HIV) infection (PLWH) remain at increased risk of developing
head and neck squamous cell cancer (HNSCC) due to oncogenic human papillomavirus (HPV) infection, despite
adequate management of HIV with effective antiretroviral therapy (ART). Clinical observations have indicated
increased risk…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click